Earlier this year, California resident Christina Robins sued wellness brand Lemme Inc. accusing it of misleading marketing practices surrounding the company’s GLP-1 Daily supplement.

Robins took action by seeking class-action status for customers who were also impacted by the practices.

The class action complaint pointed to a lack of "clinical data that supports the notion that simply boosting the amount of naturally occurring GLP-1 in the body has sustained weight-loss effects."

In the era of GLP-1 agonist medications, what can supplement companies say about products that claim to support the drugs? What are red flags when it comes to oversight? And where might gray areas exist?